Development of an EliSPOT assay for detection of CMV-specific immune response

Introduction: The Cytomegalovirus (CMV) is the major cause of morbidity and mortality in solid organ (SOT) and bone marrow (BMT) transplantation. An early reconstitution of immune response is crucial in limiting CMV replication; on the other hand, a late reconstitution may determine CMV reactivation...

Full description

Bibliographic Details
Main Authors: Maria Elena Terlizzi, Sara Astegiano, Francesca Sidoti, Stefano Gambarino, Rossana Cavallo, Cristina Costa, Massimiliano Bergallo
Format: Article
Language:English
Published: PAGEPress Publications 2010-06-01
Series:Microbiologia Medica
Subjects:
Online Access:http://www.pagepressjournals.org/index.php/mm/article/view/2462
_version_ 1818532308513193984
author Maria Elena Terlizzi
Sara Astegiano
Francesca Sidoti
Stefano Gambarino
Rossana Cavallo
Cristina Costa
Massimiliano Bergallo
author_facet Maria Elena Terlizzi
Sara Astegiano
Francesca Sidoti
Stefano Gambarino
Rossana Cavallo
Cristina Costa
Massimiliano Bergallo
author_sort Maria Elena Terlizzi
collection DOAJ
description Introduction: The Cytomegalovirus (CMV) is the major cause of morbidity and mortality in solid organ (SOT) and bone marrow (BMT) transplantation. An early reconstitution of immune response is crucial in limiting CMV replication; on the other hand, a late reconstitution may determine CMV reactivation with possible evolution to symptomatic phase.The Enzyme-Linked Immunosorbent Spot (EliSPOT) assay is a useful tool for monitoring the CMV-specific immune response recovery in transplant patients.This study propose the development and optimization of a interferon-gamma-(IFN-γ)-based EliSPOT assay for the detection of CMV immune response. Methods: CD3 + lymphocytes were separated using Robosep (negative selection, HLA ® EasySep WB Human T Cell Enrichment Kit, Stemcell Technology,Vancouver, Canada).The EliSPOT assay was optimized using the Human IFN gamma ELISPOT Kit and a modified protocol provided by Nanogen Advanced Diagnostics (Buttigliera Alta, Italy). Different parameters were analyzed: number of cells (200,000 - 300,000), antigens (CMV peptide mix and whole CMV antigen), incubation time (18 - 20 - 22 - 24h), number of washes, incubation conditions with secondary antibody and conditions of substrate development. Results: Herein we report the optimal conditions identified. 200,000 CD3+ cells per well were stimulated with CMV peptide mix antigens. Cells were stimulated for 18h at 37 °C in humidified atmosphere; wells were washed and secondary antibody was added and incubated at room temperature for 2h.After incubation a second series of washes were performed. Substrate was added and incubation for 15 minutes was carried out.The reaction was detected by plate reader AID ELISPOT (Strassberg, Germany). Conclusions:We developed an EliSPOT assay for the detection of CMV-immune response and reconstitution.All variables were compared to previous published protocols.The improvement of the EliSPOT assay for the detection of CMV-specific immune response represents the first step for result evaluation in clinical practice.
first_indexed 2024-12-11T17:43:48Z
format Article
id doaj.art-91e4e11823da4dbeb80c49b5c7ef695c
institution Directory Open Access Journal
issn 2280-6423
language English
last_indexed 2024-12-11T17:43:48Z
publishDate 2010-06-01
publisher PAGEPress Publications
record_format Article
series Microbiologia Medica
spelling doaj.art-91e4e11823da4dbeb80c49b5c7ef695c2022-12-22T00:56:26ZengPAGEPress PublicationsMicrobiologia Medica2280-64232010-06-0125210.4081/mm.2010.24621716Development of an EliSPOT assay for detection of CMV-specific immune responseMaria Elena TerlizziSara AstegianoFrancesca SidotiStefano GambarinoRossana CavalloCristina CostaMassimiliano BergalloIntroduction: The Cytomegalovirus (CMV) is the major cause of morbidity and mortality in solid organ (SOT) and bone marrow (BMT) transplantation. An early reconstitution of immune response is crucial in limiting CMV replication; on the other hand, a late reconstitution may determine CMV reactivation with possible evolution to symptomatic phase.The Enzyme-Linked Immunosorbent Spot (EliSPOT) assay is a useful tool for monitoring the CMV-specific immune response recovery in transplant patients.This study propose the development and optimization of a interferon-gamma-(IFN-γ)-based EliSPOT assay for the detection of CMV immune response. Methods: CD3 + lymphocytes were separated using Robosep (negative selection, HLA ® EasySep WB Human T Cell Enrichment Kit, Stemcell Technology,Vancouver, Canada).The EliSPOT assay was optimized using the Human IFN gamma ELISPOT Kit and a modified protocol provided by Nanogen Advanced Diagnostics (Buttigliera Alta, Italy). Different parameters were analyzed: number of cells (200,000 - 300,000), antigens (CMV peptide mix and whole CMV antigen), incubation time (18 - 20 - 22 - 24h), number of washes, incubation conditions with secondary antibody and conditions of substrate development. Results: Herein we report the optimal conditions identified. 200,000 CD3+ cells per well were stimulated with CMV peptide mix antigens. Cells were stimulated for 18h at 37 °C in humidified atmosphere; wells were washed and secondary antibody was added and incubated at room temperature for 2h.After incubation a second series of washes were performed. Substrate was added and incubation for 15 minutes was carried out.The reaction was detected by plate reader AID ELISPOT (Strassberg, Germany). Conclusions:We developed an EliSPOT assay for the detection of CMV-immune response and reconstitution.All variables were compared to previous published protocols.The improvement of the EliSPOT assay for the detection of CMV-specific immune response represents the first step for result evaluation in clinical practice.http://www.pagepressjournals.org/index.php/mm/article/view/2462EliSPOT assay, CMV, immune response
spellingShingle Maria Elena Terlizzi
Sara Astegiano
Francesca Sidoti
Stefano Gambarino
Rossana Cavallo
Cristina Costa
Massimiliano Bergallo
Development of an EliSPOT assay for detection of CMV-specific immune response
Microbiologia Medica
EliSPOT assay, CMV, immune response
title Development of an EliSPOT assay for detection of CMV-specific immune response
title_full Development of an EliSPOT assay for detection of CMV-specific immune response
title_fullStr Development of an EliSPOT assay for detection of CMV-specific immune response
title_full_unstemmed Development of an EliSPOT assay for detection of CMV-specific immune response
title_short Development of an EliSPOT assay for detection of CMV-specific immune response
title_sort development of an elispot assay for detection of cmv specific immune response
topic EliSPOT assay, CMV, immune response
url http://www.pagepressjournals.org/index.php/mm/article/view/2462
work_keys_str_mv AT mariaelenaterlizzi developmentofanelispotassayfordetectionofcmvspecificimmuneresponse
AT saraastegiano developmentofanelispotassayfordetectionofcmvspecificimmuneresponse
AT francescasidoti developmentofanelispotassayfordetectionofcmvspecificimmuneresponse
AT stefanogambarino developmentofanelispotassayfordetectionofcmvspecificimmuneresponse
AT rossanacavallo developmentofanelispotassayfordetectionofcmvspecificimmuneresponse
AT cristinacosta developmentofanelispotassayfordetectionofcmvspecificimmuneresponse
AT massimilianobergallo developmentofanelispotassayfordetectionofcmvspecificimmuneresponse